Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi´s Sarcoma
About this trial
This is an interventional treatment trial for Kaposi´s Sarcoma focused on measuring Kaposi sarcoma, HIV, Bevacizumab
Eligibility Criteria
Inclusion Criteria:
- HIV infected
- KS of the oral cavity, pharynx and larynx, histopathologically confirmed
- HIV treatment-naïve
Exclusion Criteria:
- Airway obstructive lesions
- Actively bleeding lesions
- Tumor-associated oedema or ulceration
- Gastrointestinal KS
- KS in other nonnodal viscera
Sites / Locations
- Centro de Investigacion en Enfermedades Infecciosas
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
HAART
HAART+ Bevacizumab injection
Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Patients received 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) in the target lesion every 2 weeks. Bevacizumab was injected using an insulin syringe in a submucosal plane. The volume injected was based on the size of the target lesion; the dose was 0.2 mL (5 mg) per cm2.